Price Alert

Editas Medicine Inc. (EDIT)

NASDAQ: EDIT · Real-Time Price · USD

2.63

-0.10 (-3.66%)

At close: Aug 19, 2025, 3:59 PM

2.62

-0.57%

After-hours: Aug 19, 2025, 07:44 PM EDT

-3.66% (1D)

Bid	2.62
Market Cap	236.94M
Revenue (ttm)	35.84M
Net Income (ttm)	-251.23M
EPS (ttm)	-2.84
PE Ratio (ttm)	-0.93
Forward PE	-2.05
Analyst	Hold

Ask	2.7
Volume	1,329,927
Avg. Volume (20D)	2,616,667
Open	2.71
Previous Close	2.73
Day's Range	2.60 - 2.71
52-Week Range	0.91 - 4.15
Beta	2.20

About EDIT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EDIT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EDIT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Editas Medicine has released their quartely earnings on Aug 12, 2025:

Revenue of $3.58M exceeds estimates by $2.16M, with 597.47% YoY growth.

EPS of -0.63 misses estimates by -0.24, with 23.17% YoY growth.

Next Earnings Release

Editas Medicine Inc. is scheduled to release its earnings on Nov 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+34.5%

Editas Medicine shares are trading higher after th... Unlock content with Pro Subscription

8 months ago

-23.81%

Editas Medicine shares are trading lower after Stifel and Chardan Capital downgraded the stock and multiple firms cut their respective price targets.

News

4 days ago · fool.com

Why Editas Medicine Stock Was Skyrocketing This Week

Gene-editing company Editas Medicine (EDIT -4.06%) was something of an unexpected star on the stock exchange as the trading week came to a close. The small biotech's share price was up by a robust 34%...

1 week ago · zacks.com

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.82 per share a year ago.

1 week ago · fool.com

Can This Beaten-Down Stock Bounce Back?

Editas Medicine (EDIT 2.50%), a small-cap biotech company, is up by 81% since January. But zooming out gives us a completely different picture.

2 weeks ago · zacks.com

Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?

Here is how Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

2 weeks ago · zacks.com

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

An updated edition of the June 27, 2025, article.

1 month ago · fool.com

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Investors looking for stocks that can produce dramatic gains in a short amount of time will want to turn their heads toward the biopharmaceutical space. Chasing short-term gains isn't the smartest way...

1 month ago · fool.com

2 Beaten-Down Stocks to Avoid

Over the past year, Editas Medicine (EDIT -3.20%) and Sarepta Therapeutics (SRPT -1.38%), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatili...

2 months ago · fool.com

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine (EDIT 6.94%) ...

2 months ago · zacks.com

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

2 months ago · fool.com

1 Stock Down 97% That Could Double, According to Wall Street

Over the past few years, investors have moved away from somewhat speculative and unprofitable companies to put their money into safer, steadier investments. Editas Medicine (EDIT -4.01%), a gene-editi...

Load More News